Research
Hormonal
GLP-1 receptor agonists (GLP-1RA) and Sodium-glucose cotransporter-2 inhibitors (SGLT2i) provide cardiovascular and renal benefits in T2D patients, whereas sulphonyureas are associated with increased cardiovascular mortality.
If you have Type 2 Diabetes and heart or kidney issues, ask your doctor about GLP-1RA or SGLT2i medications, as they protect your heart and kidneys. Avoid sulphonyureas if possible, as they may increase cardiovascular risk.
StrongSupportsVERY_HIGH confidence
Therapies within the GLP-1RA and SGLT2i classes have the strongest evidence to support cardiovascular benefit in people with T2D... Compared with other treatments, sulphonyurea use in people with T2D was associated with increased cardiovascular and all-cause mortality.
Why this rating
Cites dedicated Cardiovascular Outcome Trials (CVOTs) and meta-analyses.
Source
Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations
David M. Williams et al. · Dove Medical Press (Taylor and Francis Group) · 2022
narrative_reviewCited 102×
Read the paper More from this paper
- Personalized Type 2 Diabetes management, which tailors pharmacotherapy to individual phenotypic, clinical, and personal factors, improves medication adherence, patient satisfaction, and health outcomes compared to rigid algorithmic approaches.Good
- Personalized glycemic targets should be less aggressive in older patients or those with reduced life expectancy to minimize hypoglycemia risk and polypharmacy burden.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →